NCT02724878View on ClinicalTrials.gov

Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

July 15, 2016

Primary Completion Date

November 13, 2019

Study Completion Date

December 31, 2024

Conditions
Advanced Non-Clear Cell Kidney Cancer
Interventions
DRUG

Bevacizumab

DRUG

Atezolizumab

Trial Locations (4)

48201

Karmanos Cancer Institute, Detroit

92037

University of California, San Diego Moores Cancer Center, La Jolla

02115

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER